Radiation plus chemo after liver surgery for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies giving a special internal radiation treatment along with capecitabine (a chemotherapy) for liver cancer related to bile ducts, after planned surgical removal. It may help improve control of the cancer in cases where surgeons think the edges of the removed tumor may be too close.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old
- You must have confirmed intrahepatic cholangiocarcinoma (a specific type of bile-duct liver cancer) from biopsy or surgery
- You should not have had any previous treatment for this bile-duct liver cancer
- Your cancer should be considered removable by a liver surgery specialist, with a high risk of close surgical margins (edges)
- Your blood tests, liver function, kidney function, and clotting must meet safety limits
- You must be able to follow the study plan and provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (durvalumab, cisplatin, and gemcitabine, with or without futibatinib) given before surgery to treat intrahepatic cholangiocarcinoma—a rare cancer of the bile ducts inside the liver. The goal is to shrink the tumor and improve outcomes after surgery.
This trial tests giving chemotherapy (cisplatin and gemcitabine) combined with an immunotherapy drug (rilvegostomig) before and after surgery for a type of bile duct cancer called intrahepatic cholangiocarcinoma that has a high risk of coming back. The goal is to see if this combination can reduce the chance of cancer returning.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
Hear when a new Resectable Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.